GE Healthcare’s Discovery NM750b molecular breast scanner
GE Xeleris 4 DR workstation
SmartBreast today announced that it has acquired GE Healthcare (NYSE:GE)’s molecular breast imaging assets for an undisclosed amount.
GE Healthcare’s MBI system has developed a positive reputation for helping physicians with the detection of cancer lesions in dense breast tissue,” Erez Levy, GM of nuclear medicine at GE Healthcare, said in a news release. “We are proud of this system’s legacy and will continue to support its mission with our world-class Cadmium Zinc Telluride (CZT) detectors for SmartBreast’s use in the MBI system.”
Molecular breast imaging is used to detect breast cancer earlier in people with dense breast tissue. It images through the tissue to find cancers that mammography misses. In one clinical study, researchers at the Mayo Clinic found that mammography found 3.2 cancers per 1,000 people with dense breasts. Adding low-dose MBI increased the found cancers to 12 per 1,000 people.